Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, what assessment she has made for the implications for her policies of the recent analysis published by WPI Economics: False Economy Report on the impact of rebate rates under the Voluntary and Statutory Schemes for Branded Medicines Pricing and Access on the level of future R&D investment.

The Department carefully considers all evidence in the public domain on matters relating to the growth and competitiveness of the UK Life Science sector, including the recent report by WPI Strategy. This happens in combination with broad engagement with individual companies, the NHS and with charities and patient representatives, and will continue in future as part of the delivery of the Government’s Life Science Vision.